Tokyo - Delayed Quote JPY

JCR Pharmaceuticals Co., Ltd. (4552.T)

544.00 +33.00 (+6.46%)

At close: October 30 at 3:30:00 PM GMT+9

JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

Business Wire 17d ago

4552.T
+6.46%
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

Business Wire 29d ago

4552.T
+6.46%
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy

Business Wire 1mo ago

4552.T
+6.46%
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

Business Wire 3mo ago

4552.T
+6.46%
Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

GlobeNewswire 5mo ago

4552.T
+6.46%
4506.T

4503.T
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

Business Wire 1mo ago

4552.T
+6.46%
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform

Exec Edge 3mo ago

ABOS

4552.T
+6.46%
BIIB
Slate Medicines Appoints Mark W. Hahn to Board of Directors

Exec Edge 3mo ago

BIIB

ROP.SW

DNLI
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

GlobeNewswire 3mo ago

ABOS

4552.T
+6.46%
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Business Wire 4mo ago

ABOS

4552.T
+6.46%
4552
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Moby 7mo ago

ABOS

4552.T
+6.46%
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference

MarketBeat 7mo ago

ABOS

4552.T
+6.46%

U.S. markets closed

JCR Pharmaceuticals Co., Ltd. (4552.T)

JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy

JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform

Slate Medicines Appoints Mark W. Hahn to Board of Directors

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform

Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference